What Lorbrena Treats: Main Uses and Benefits

Lorbrena is used for the management of advanced Non-Small Cell Lung Cancer (NSCLC) that tests positive for the ALK gene rearrangement. It is indicated for use in conditions where therapeutic support is needed for this specific cancer type. This therapy is relevant in contexts where patients present with metastatic disease, progression after prior targeted therapies, or cancer spread to the central nervous system. This targeted approach supports the patient during difficult episodes by easing the overall symptom load.

Control of Advanced and Drug-Resistant Disease

Lorbrena is generally considered relevant across conditions presenting with advanced or metastatic ALK-positive NSCLC, which may include situations where the cancer has developed resistance mutations following treatment with earlier therapies. It is applied in clinical settings that involve unstable symptom patterns and may assist with addressing symptom clusters that become more disruptive during disease flare-ups. This approach helps maintain a sense of stability when symptoms are more noticeable, contributing to easing the overall symptom burden.

Management of Central Nervous System Spread

This targeted approach is relevant for easing symptoms related to increased neurological activity caused by CNS metastases (cancer spread to the brain). In this therapeutic context, Lorbrena provides supportive relief and is applied in scenarios where additional management of discomfort within the CNS is required. This supports the patient by playing a role in managing tumor activity in the brain, assists with maintaining functional stability, and contributes to easing overall day-to-day comfort.

Regulatory References

1. European Medicines Agency (EMA) overview

Eligibility scope

Official Eligibility Statements

Lorbrena is officially indicated only for adult patients whose tumors are confirmed to be ALK-positive. The medicine is contraindicated in patients who are concurrently taking strong CYP3A inducers due to regulatory warnings regarding serious liver risk. Its use is not recommended in the pediatric population as safety has not been established. Furthermore, the official label requires special consideration for patients with severe renal impairment or certain pre-existing conditions like uncontrolled hypertension or hyperglycemia, which may require monitoring or discontinuation to maintain eligibility.

Interactions with other medicines and products

The official regulatory profile for Lorbrena is defined by its significant interaction with the Cytochrome P450 3A (CYP3A) enzyme system, which can alter the concentration of both Lorbrena and other co-administered medicinal products.

Contraindicated Combinations and Timing Rules

Lorbrena is contraindicated (must not be co-administered) with Strong CYP3A Inducers (e.g., Rifampin), a prohibition driven by the potential for serious liver toxicity. This category includes certain herbal products like St. John’s Wort. To safely start Lorbrena, a mandatory waiting period is required where the Strong CYP3A Inducer must be discontinued for a time equivalent to 3 plasma half-lives of that substance.

Exposure Modification and Effects on Other Drugs

• Increase in Lorlatinib Exposure: Co-administration with Strong CYP3A Inhibitors (e.g., Itraconazole) substantially increases Lorlatinib’s plasma concentration, necessitating avoidance or careful modification of the Lorlatinib regimen.
• Decrease in Lorlatinib Exposure: Moderate CYP3A Inducers can cause a decrease in Lorlatinib concentration, which also requires avoidance or a necessary adjustment to the Lorlatinib regimen.
• Decrease in Other Drugs: Lorlatinib is a moderate inducer of both CYP3A enzymes and the P-glycoprotein (P-gp) transporter. This results in a reduction of the plasma concentration of other medicines that are substrates of these systems, requiring avoidance when minimal concentration changes may lead to serious therapeutic failures. Additionally, food products like Grapefruit juice may increase Lorlatinib’s concentration.

The mechanism of action for Lorlatinib centers on its selective activity as a macrocyclic tyrosine kinase inhibitor (TKI). The primary targets are the Anaplastic Lymphoma Kinase (ALK) and ROS1 kinase enzymes. Lorlatinib employs a competitive blockade mechanism by binding within the ATP-binding pocket of the kinase domain. This prevents the enzyme's necessary autophosphorylation and subsequent activation of downstream growth and survival pathways, specifically the RAS/MAPK and PI3K/AKT cascades. The resulting loss of signaling forces cells dependent on the ALK/ROS1 pathway into cell cycle arrest and apoptosis (programmed cell death). A key structural characteristic of the drug is its ability to maintain binding affinity against enzyme alterations, such as the ALK G1202R substitution, ensuring sustained inhibitory activity. Furthermore, Lorlatinib possesses the physical properties required to traverse the blood-brain barrier (BBB). This brain-penetrant mechanism permits the inhibitory action to be effectively applied to target-expressing cells within the Central Nervous System (CNS) tissue, achieving comprehensive systemic and CNS modulation of the targeted enzyme pathways.

Administration and Standard Dosing

Lorbrena is administered orally in the form of a film-coated tablet. The recommended standard starting dose for adult patients is 100 mg taken once daily. To maintain consistent systemic exposure, the medication should be consumed at approximately the same time each day, and it may be taken with or without food.

Procedural Instructions and Schedule

Proper administration requires that the tablets be swallowed whole; they must not be chewed, crushed, or split under any circumstances. Should a dose be missed, the patient should take it as soon as remembered, unless the next scheduled dose is due within 4 hours, in which case the missed dose must be skipped. Patients must not attempt to make up for a missed dose by taking two doses at once. If vomiting occurs shortly after a dose, no additional dose should be taken, and the regular schedule should be continued.

Use Duration and Adjustments

Treatment is typically considered long-term, intended to continue until either documented disease progression or the onset of unacceptable side effects necessitates permanent discontinuation. Dose adjustments are defined for specific patient populations and conditions. For instance, a reduced starting dose of 75 mg once daily is mandated for patients with severe renal impairment or when the medication is co-administered with a strong CYP3A inhibitor. Further dose reductions, down to 75 mg and 50 mg once daily, are used for managing adverse reactions, but no specific initial dose change is required for older adults.

Lorbrena (lorlatinib) is a tyrosine kinase inhibitor (TKI) primarily investigated for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC). Research supporting its use includes data from the pivotal Phase 3 CROWN trial, which compared lorlatinib to crizotinib in patients who had not previously received systemic treatment for metastatic ALK-positive NSCLC.

Efficacy Findings from the CROWN Trial

Clinical trials have evaluated lorlatinib's effects on disease progression and tumor response, including spread to the central nervous system (CNS). Key reported findings from the CROWN study (5-year follow-up) are summarized below:

• Progression-Free Survival (PFS): The median PFS was not reached for lorlatinib, compared with 9.1 months for crizotinib. At five years, the probability of being alive without disease progression was 60% for patients who received lorlatinib versus 8% for those who received crizotinib.
• Intracranial Activity: Lorlatinib demonstrated notable activity against brain metastases. The median time to intracranial progression was not reached in the lorlatinib group, compared with 16.4 months in the crizotinib group. Among patients without brain metastases at the start of the study, 92% of those treated with lorlatinib were free from intracranial progression at 60 months.

Other Relevant Research

Lorlatinib was also studied in previously treated patients whose ALK-positive NSCLC had progressed on other ALK inhibitors. The drug has been shown to be active against multiple ALK resistance mutations, a mechanism thought to contribute to its activity in the brain and in later lines of therapy. Overall survival data from the CROWN trial remains under evaluation as the required number of events to trigger a final analysis has not yet been reached.

Common questions about Lorbrena (FAQ)

Q: How does Lorbrena differ from older ALK medicines?

Official documents describe Lorbrena as a third-generation ALK TKI, meaning it is a newer type of targeted medicine. The drug is described as being active against ALK resistance mutations, which may develop during treatment with previous ALK inhibitors. Additionally, it has the chemical properties that allow it to penetrate the blood-brain barrier to address disease in the central nervous system.

Q: Can Lorbrena cause issues with vision?

Regulatory documents report that a vision disorder is a possible adverse reaction. This can involve symptoms like blurred vision, double vision, or a reduction in visual sharpness. These effects are documented in the official labeling and are typically managed by a healthcare provider.

Q: Does Lorbrena affect fertility?

Based on studies conducted in animals, official labeling notes that Lorbrena may cause a temporary impairment of fertility in males. Official product information on the potential effects on female fertility is limited or not available in the regulatory summary.

Q: Can Lorbrena interact with heart medications?

Lorbrena is described as a moderate inducer of the CYP3A enzyme, which can lower the concentration of other medicines, including certain heart medications, that are broken down by this system. Furthermore, official information advises that monitoring of heart rhythm (ECG) and blood pressure may be necessary due to the potential for cardiac events like AV block.

Q: Can Lorbrena be taken by patients who also have diabetes?

Lorbrena can cause hyperglycemia, which means high blood sugar. Because of this, official product information specifies that patients who have a pre-existing condition, such as uncontrolled high blood sugar, require special consideration. This monitoring is detailed in the official guidance for patient management.

Q: What is meant by 'acquired resistance' to Lorbrena?

The term 'resistance' is used in official materials to describe when tumor cells continue to grow despite being treated with a medicine. Lorbrena was specifically designed to be active against ALK resistance mutations that have been acquired after treatment with older ALK inhibitors.

Q: What is the risk of having a serious interaction with Lorbrena?

Regulatory documents state that Lorbrena is contraindicated (must not be used) with strong CYP3A enzyme inducers, which are certain other drugs or herbal supplements. This prohibition is due to a specific warning about the potential risk of severe liver damage, known as hepatotoxicity.

Q: Is Lorbrena considered chemotherapy?

Lorbrena is classified by regulatory bodies as a Tyrosine Kinase Inhibitor (TKI), which is a type of targeted therapy. Targeted therapies are designed to specifically block certain molecules in cancer cells and work differently than traditional chemotherapy.

Q: How quickly is Lorbrena expected to start working?

Official documents do not provide a single timeline for the start of tumor response. However, clinical trial data includes the median time to the onset of certain effects, such as two weeks for increased triglycerides or 1.5 months for swelling.

Q: What is the form of the medicine (pill, liquid, injection)?

Lorbrena is supplied as a film-coated tablet that is taken by mouth. It is administered orally and is not available as a liquid or injection.

Q: Is it possible to become resistant to Lorbrena over time?

Studies and official information indicate that the drug's activity is assessed until disease progression or unacceptable side effects occur. The drug is monitored in long-term clinical trials to assess its continued activity against the disease.

Q: Why do doctors use Lorbrena after other treatments have been tried?

Official labeling supports the use of Lorbrena in patients whose ALK-positive lung cancer has progressed after initial treatment with certain other ALK inhibitors. This use is based on research showing its activity against the acquired resistance mutations that can cause the previous treatments to stop working.

Q: What kind of monitoring is needed while taking Lorbrena?

Official guidance requires regular monitoring during treatment. This includes checking blood pressure, blood sugar (glucose) levels, cholesterol and triglyceride levels, and heart rhythm using an ECG. Patients are also monitored for any changes to the nervous system.

Q: Is Lorbrena used for other types of cancer besides lung cancer?

According to the official prescribing information, Lorbrena is currently indicated for the treatment of adult patients with ALK-positive metastatic non-small cell lung cancer (NSCLC).

Q: What is the success rate described in research for Lorbrena?

Official research documents report specific measures of the drug's performance. These include the Overall Response Rate (ORR) (the percentage of patients with tumor shrinkage) and the 5-year Progression-Free Survival (PFS) rate (the percentage of patients alive without the disease getting worse at that time point).

Q: What happens if Lorbrena is stopped suddenly?

Official instructions specify that patients should not stop taking Lorbrena or change the dose without guidance from a healthcare provider. The official guidance describes dose adjustments, temporary stopping (withholding), or permanent discontinuation as steps for managing side effects.

Q: Is Lorbrena available as a generic drug?

Official drug records currently list the active ingredient, Lorlatinib, only under the brand name Lorbrena. A generic version is not listed in official sources at this time.

Q: Can Lorbrena cause liver problems?

Yes, official safety labeling reports a risk of Hepatotoxicity, or liver damage, as a serious adverse reaction. Patients who are taking other medicines that affect the liver may require additional monitoring.

Q: What is the chemical name for Lorbrena?

The active ingredient in Lorbrena, which is Lorlatinib, has a long formal chemical name that describes its molecular structure. This name is provided in scientific databases and official drug records.

Q: Are headaches a common side effect of Lorbrena?

Headaches are reported in some patient information sources as a potential side effect. Since high blood pressure is listed as a common adverse reaction, and headaches can be a symptom of high blood pressure, monitoring is often required during treatment.

Q: Can Lorbrena affect the ability to drive or operate machinery?

Official information notes that Lorbrena can cause side effects such as vision changes, dizziness, and central nervous system (CNS) effects. Due to these possible effects, official patient information often includes cautions regarding driving or operating heavy machinery.

Q: What are the typical patient populations studied in Lorbrena trials?

Clinical trial summaries describe the characteristics of patients involved in the studies. This information includes patient demographics, such as the median age, the specific type of lung cancer (adenocarcinoma), and whether the disease had spread to the brain at the start of the study.

How to Store and Dispose of Lorbrena

Lorbrena (lorlatinib) tablets require specific environmental control to maintain stability, and its disposal must adhere to specialized protocols for medicinal waste.

Storage Conditions and Requirements

Lorbrena must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). Permitted temperature excursions are allowed between 15 C and 30 C. The medication must be kept out of the reach of children, and the tablets should remain in the original bottle, which features a child-resistant closure. No explicit restrictions regarding light, moisture, or refrigeration are detailed beyond the required temperature control.

Disposal Instructions

As an antineoplastic agent, Lorbrena must not be disposed of in household waste or via wastewater. Unused medicine and waste material must be handled and discarded in accordance with local requirements for cytotoxic medicines.